GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Recommendation of “Moderate Buy” from Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $87.4286.

Several research analysts have recently issued reports on WGS shares. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and set a $63.00 target price (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. TD Cowen restated a “buy” rating on shares of GeneDx in a research report on Wednesday, July 15th. Finally, Wall Street Zen downgraded shares of GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Several law firms reiterated that a securities class action has been filed against GeneDx and certain executives on behalf of investors who bought shares between April 16, 2025, and May 4, 2026. The complaints allege violations of U.S. securities laws and seek damages for investors; the allegations have not been proven. Securities class action announcement
• Negative Sentiment: The central allegations concern GeneDx’s acquisition of Fabric Genomics. Investors claim the company misrepresented the expected benefits and financial impact of the acquisition, while subsequent reassessment exposed a gap between acquisition promises and operating results. One notice associated the allegations with a roughly 49% decline in WGS shares during the relevant period. WGS shareholder alert
• Neutral Sentiment: The repeated notices from Bragar Eagel & Squire, Robbins LLP, Kahn Swick & Foti, Hagens Berman, Faruqi & Faruqi, DJS Law Group, Rosen Law Firm and Bronstein, Gewirtz & Grossman primarily encourage affected investors to contact counsel before the August 3 lead-plaintiff deadline. These announcements do not represent a new operating update or a final court determination. GeneDx class action deadline notice

Insider Buying and Selling

In other GeneDx news, Director Casdin Capital, Llc bought 185,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were bought at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the transaction, the director directly owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Keith A. Meister purchased 533,758 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were acquired at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This represents a 16.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 2,256,420 shares of company stock worth $93,144,340 and sold 21,699 shares worth $1,295,646. 25.17% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in GeneDx during the 4th quarter worth approximately $27,000. Fifth Third Bancorp bought a new position in GeneDx in the first quarter worth approximately $31,000. Quarry LP grew its stake in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after acquiring an additional 209 shares during the period. Ramirez Asset Management Inc. acquired a new stake in GeneDx in the fourth quarter valued at approximately $33,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $33,000. 61.72% of the stock is owned by institutional investors.

GeneDx Stock Performance

Shares of NASDAQ:WGS opened at $60.54 on Tuesday. The company’s 50 day simple moving average is $59.11 and its 200 day simple moving average is $71.49. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -22.59 and a beta of 1.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. GeneDx has a 1 year low of $32.21 and a 1 year high of $170.87.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, research analysts predict that GeneDx will post -1 EPS for the current fiscal year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.